Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO
- Novor V2.0 software with novel ML algorithm trained on HLA peptides yields immunopeptidome from de novo peptide sequencing with further improved IDs
- TwinScape ™ digital-twin technology with iRT ™ standards supports highest timsTOF performance with intelligent feedback – well beyond ‘just up-time’
- New glyco-PASEF®method for ultra-high sensitivity 4D glycopeptide analysis
-
Spectronaut® 18
software now available for
Bruker ProteoScape ™ users - Biognosys launches high-throughput ENRICHMENT plasma proteomics service for large-scale quantification of ~4.5k proteins with ~55k peptides at 1% FDR specificity
- PreOmics® sample prep tools for proteomics now with >50 BeatBox® placements for fast cell lysis and affordable, high-performance FFPE/FF tissue homogenization
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311088724/en/
Bruker's Immunopeptidomics Workflow (Graphic: Business Wire)
The advances featured at US HUPO include improved machine-learning de novo sequencing (Novor V2.0), a novel high-performance monitoring digital-twin software (TwinScape), the new glyco-PASEF method for high-sensitivity glycopeptide analysis, and access to Spectronaut 18 for users of BrukerProteoScape, a GPU-powered software for real-time 4D proteomics, now with access to library-free searches by Biognosys directDIA®.
A. Advancing Cancer Immunotherapy Research
Bruker enhances its timsTOF HT and timsTOF Ultra systems with the new software Novor v2.0 for de novo immunopeptidomic profiling. Novor v2.0, developed in collaboration with
Dr.
TwinScape is a new digital-twin performance monitoring and quality control engine, leveraging iRT peptide standards to support sustained peak performance in sample prep and LC-MS. For synergistic multi-omics studies in the post-genomic era, a combination of depth of coverage, robustness, and scalable quantitation is required. TwinScape enables larger controlled studies and valid cross-lab comparability.
Dr.
Bruker presents the novel timsTOF glyco-PASEF method with polygon filtering developed with the
Dr.
Bruker is now offering GlycoScape™ real-time glycoproteomic software, developed with
Bruker also announces that the MSFragger-Glyco software now supports timsTOF data. Dr. Alexey Nesvizhskii, Professor of Computational Medicine, Bioinformatics and Pathology at
D. Software Advances for dia-PASEF®
The newest release of Bruker ProteoScape makes a Spectronaut 18 module available for dia-PASEF analysis, enabling real-time results using GPU computing, including directDIA for library-free searches. Bruker ProteoScape now also upgrades TIMS DIA-NN software to version 3.0 with improved quantitation accuracy.
About
Bruker (Nasdaq: BRKR) is enabling scientists to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311088724/en/
Media Contact
T: +49 (421) 2205-2843
E: petra.scheffer@bruker.com
Investor Relations Contact
Sr. Director Investor Relations &
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Source: